Novo Nordisk's pricing approaches in the U.S. have drawn sharp criticism from lawmakers like Senator Sanders, who has accused the company of rate gouging, pointing out the stark contrast among U.S. costs and those in Europe and copyright. Scientific tests of Rybelsus and copyright have re